Argenta Discovery and PRECOS Establish Cancer Drug Discovery Alliance
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Argenta Discovery and PRECOS announced they have entered into an alliance to provide exceptional cancer drug discovery services and expertise on a fee-for-service basis.
The collaboration enables Argenta and PRECOS to undertake complete, integrated oncology-focused drug discovery programmes for their contract research clients, from hit finding to in vivo ‘proof-of-concept’.
Dr. Christopher Ashton, Chief Executive Officer of Argenta Discovery said, "Argenta has undertaken many successful medicinal chemistry-driven cancer drug discovery contract research projects in the past, but we have been looking at ways of enhancing our capabilities in this therapeutic area, where there is still considerable unmet medical need. Argenta has partnered with PRECOS to provide clients with dedicated access to specialist in vitro, ex vivo and in vivo cancer models and expertise, offered by a world leader in the field.”
“We have several ongoing cancer-focused contract research programmes and a number of projects in the pipeline which are likely to benefit from PRECOS’ support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with PRECOS.”
The collaboration enables Argenta and PRECOS to undertake complete, integrated oncology-focused drug discovery programmes for their contract research clients, from hit finding to in vivo ‘proof-of-concept’.
Dr. Christopher Ashton, Chief Executive Officer of Argenta Discovery said, "Argenta has undertaken many successful medicinal chemistry-driven cancer drug discovery contract research projects in the past, but we have been looking at ways of enhancing our capabilities in this therapeutic area, where there is still considerable unmet medical need. Argenta has partnered with PRECOS to provide clients with dedicated access to specialist in vitro, ex vivo and in vivo cancer models and expertise, offered by a world leader in the field.”
“We have several ongoing cancer-focused contract research programmes and a number of projects in the pipeline which are likely to benefit from PRECOS’ support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with PRECOS.”
